Last Updated: July 17, 2020
In addition to the antiviral medications and the immune-based therapies for the treatment of COVID-19 that are discussed elsewhere in the COVID-19 Treatment Guidelines, adjunctive therapies are frequently used in patients with COVID-19 to prevent and/or treat the infection or its complications. Some of these agents are being studied in clinical trials.
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a prothrombotic state and an increased incidence of thromboembolic disease. Antithrombotic Therapy in Patients with COVID-19 reviews the existing data and provides recommendations for the care of individuals who were receiving antithrombotic agents before they acquired SARS-CoV-2 and those who need these therapies to prevent or treat thromboembolic events during course of the infection.
Some clinicians advocate for the use of vitamin and mineral supplements to treat respiratory viral infections. Multiple ongoing studies are evaluating the use of vitamin and mineral supplements for both the treatment and prevention of SARS-CoV-2 infection.
The following sections describe the underlying rationale for the use of adjunctive therapies and summarize the existing clinical trial data. Additional adjunctive therapies will be added as new evidence emerges.